J Korean Oncol Nurs.  2011 Nov;11(3):254-262.

Quality of Life in Colorectal Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy

• Kim JH
• Choi KS
• Kim TW
• Hong YS

Abstract

PURPOSE
The purpose of this study was to identify the quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy.
METHODS
A total of 93 patients were recruited in the cross-sectional survey design. Quality of life in colorectal cancer patients were measured by European Organization for Research and Treatment of Cancer (EORTC) QLQ C30 and CIPN20.
RESULTS
In the QLQ C30, the mean score of the global health status was 59.41, the functional scale was 73.29 and symptom scale was 26.72. In CIPN20, the mean score of sensory scale was 32.70, autonomic scale was 22.88 and motor scale was 16.12. In the QLQ C30, the global health status showed significant differences according to surgery (p=.027) and the functional scale, and the symptom scale showed significant differences according to gender (p=.046, p=.020) and nonpharmacologic intervention (p=.001, p=.009). The CIPN20, the sensory scale showed significant differences according to age (p=.006), DM (p=.005), grade of CIPN (p=<.001) the status of chemotherapy (p=.001) and nonpharmacologic intervention (p=.010).
CONCLUSION
The level of quality of life in colorectal cancer patients with peripheral neuropathy was relatively low. There is a need for developing a nursing intervention for colorectal cancer patients to improve their quality of life and to decrease chemotherapy-induced peripheral neuropathy.

Keyword

Chemotherapy; Peripheral Neuropathy; Quality of Life; Colorectal Cancer

MeSH Terms

Colorectal Neoplasms
Cross-Sectional Studies
Humans
Peripheral Nervous System Diseases
Quality of Life

Reference

1. National Cancer incidence DB, KCCR. accssed on1 October 2010. Available at: http://ncc.re.kr/manage/manage03_033_view.jsp?bbsnum=150&hSelSearch=&hTxtKeyword=&current_page=1&cd=null.

2. Hamashima C. QOL of postoperative rectal cancer: Long-term quality of life of postoperative rectal cancer patients. J Gastroenterol Hepatol. 2002. 17:571–576.

3. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005. 41:1135–1139.

4. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008. 44:1507–1515.

5. Wickham R. Chemotherapy-Induced Peripheral Neuropathy: A Review and Implications for Oncology Nursing Practice. Clin J Oncol Nurs. 2007. 11:361–376.

6. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007. 11:901–913.

7. Meyer RR, Roller J, Poppas M. Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs. 2008. 12:243–247.

8. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2010. 19:833–841.

9. Bouvier AM, Jooste V, Bonnetain F, Cottet V, Bizollon MH, Bernard MP, et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer. 2008. 113:879–886.

10. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2011. 12:[Epub ahead of print].

11. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Charateristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2010. 10:231–238.

12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993. 85:365–376.

13. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004. 13:863–868.

14. Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M. Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma. 2010. 51:2012–2020.

15. Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinicacid: results of a randomised phase III trial. Qual Life Res. 2009. 18:853–861.

16. Browall M, Ahlberg K, Karlsson P, Danielson E, Persson LO, Gaston-Johansson F. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs. 2008. 12:180–189.

17. Kato J, Nagahara A, Iijima K, Yoshimura M, Osada T, Yoshizawa T, et al. Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan. J Gastroenterol Hepatol. 2008. 23:S268–S272.

18. Tiv M, Puyraveau M, Mineur L, Calais G, Maingon P, Bardet E, et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010. 14:530–534.

19. Kim HK. Health-related quality of life and its related factors in patients with rectal cancer [dissertation]. 2003. Seoul: Yonsei Univ..

20. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010. 21:877–881.

21. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-Induced Peripheral Neuropathy. Oncol Nurs Forum. 2005. 32:305–311.

22. Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy-induced peripheral neuropathy; a systematic review of psychometric properties. J Peripher Nerv Syst. 2010. 15:314–325.